Page last updated: 2024-08-24

triazoles and Myelodysplastic Syndromes

triazoles has been researched along with Myelodysplastic Syndromes in 135 studies

Research

Studies (135)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.74)	18.7374
1990's	0 (0.00)	18.2507
2000's	32 (23.70)	29.6817
2010's	95 (70.37)	24.3611
2020's	7 (5.19)	2.80

Authors

Authors	Studies
Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H	1
Han, B; Zhang, R	1
Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE	1
Ades, L; Attalah, H; Chermat, F; Cluzeau, T; Cross, M; Descot, A; Fenaux, P; Giagounidis, A; Gloaguen, S; Götze, KS; Jentzsch, M; Kayser, S; Kubasch, AS; Medyouf, H; Metzeler, KH; Peterlin, P; Platzbecker, U; Puttrich, M; Schipp, D; Schneider, M; Sebert, M; Sockel, K; Teipel, R; Tirado-Gonzalez, I; van de Loosdrecht, A; Weigert, A	1
Bivins, CA; Borthakur, G; Bose, P; Daver, N; Estrov, Z; Huang, X; Kadia, TM; Kantarjian, HM; Konopleva, M; Kontoyiannis, DP; Marx, KR; Masarova, L; McCue, D; Naqvi, K; Pemmaraju, N; Pierce, SA; Qiao, W; Rausch, CR; Ravandi, F; Takahashi, K; Wiederhold, NP; Wurster, S; Yilmaz, M	1
Artz, AS; Bishop, M; Cooperrider, JH; Fulton, N; Kosuri, S; Larson, RA; Liu, H; Stock, W	1
Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J	1
Angelucci, E; Balleari, E; Breccia, M; Clissa, C; Cortelezzi, A; Fenu, S; Finelli, C; Levis, A; Mansueto, G; Marziano, G; Maurillo, L; Milella, MR; Musto, P; Niscola, P; Poloni, A; Ricco, A; Rivellini, F; Sanna, A; Santini, V; Scapicchio, D; Simeon, V; Tarantini, G; Venditti, A; Villani, O; Voso, MT	1
Rose, C	1
Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J	1
Aoun, M; Cornely, OA; Geddes, M; Grigg, A; Haider, S; Hammond, SP; Heinz, WJ; Hepler, DA; Kartsonis, NA; Maertens, J; Meyer, RG; Mullane, KM; Ostermann, H; Raad, I; Robertson, MN; Schanz, U; Ullmann, AJ; Van Iersel, MLPS; Waskin, H; Zimmerli, S	1
Amat, P; Calabuig, M; Hernández-Boluda, JC; Navarro, D; Pérez-Martínez, A; Solano, C; Tormo, M	1
Leitch, HA; Wong, SA	1
Gattermann, N	1
Alakel, N; Behre, G; Buchheidt, D; Christopeit, M; Cornely, OA; Hasenkamp, J; Kiehl, M; Koldehoff, M; Krause, SW; Lehners, N; Löhnert, AY; Maschmeyer, G; Mayer, K; Mellinghoff, SC; Ostermann, H; Panse, J; Penack, O; Ruhnke, M; Teschner, D; Ullmann, AJ; von Lilienfeld-Toal, M; Wolf, HH	1
Chen, J; Qian, L; Shen, J; Yang, X; Zhang, Y	1
Belli, AA; Dere, Y; Karakus, V; Polat, AK	1
Ader, F; Aguado, JM; Akova, M; Arendrup, MC; Arikan-Akdagli, S; Barnes, RA; Beigelman-Aubry, C; Blot, S; Bouza, E; Brüggemann, RJM; Buchheidt, D; Cadranel, J; Castagnola, E; Chakrabarti, A; Cornely, OA; Cuenca-Estrella, M; Denning, DW; Dimopoulos, G; Fortun, J; Gangneux, JP; Garbino, J; Groll, AH; Heinz, WJ; Herbrecht, R; Heussel, CP; Kibbler, CC; Klimko, N; Kullberg, BJ; Lagrou, K; Lange, C; Lass-Flörl, C; Lehrnbecher, T; Lewis, RE; Löffler, J; Lortholary, O; Maertens, J; Marchetti, O; Meis, JF; Munoz, P; Pagano, L; Ribaud, P; Richardson, M; Roilides, E; Ruhnke, M; Sanguinetti, M; Sheppard, DC; Sinkó, J; Skiada, A; Ullmann, AJ; Vehreschild, MJGT; Verweij, PE; Viscoli, C; Warris, A	1
Berman, E; Epstein, DJ; Frattini, MG; Huang, YT; Klimek, VM; Papanicolaou, GA; Park, JH; Seo, SK; Tallman, MS	1
Ahuja, T; Cirrone, F; Papadopoulos, J; Phillips, K; Siegfried, J	1
Kwa, LHA; Lee, HLW; Lim, TP; Tan, BH; Tan, SYM; Tan, TT; Tang, SLS; Wong, GC; Zhou, PY	1
Alimena, G; Breccia, M	1
Barreto, JN; Beach, CL; Hogan, WJ; Litzow, MR; Merten, JA; Tosh, PK; Wilson, JW; Wolf, RC	1
Kami, M; Kobayashi, K; Nishikawa, Y; Okuda, S; Takebayashi, C; Tanimoto, T	1
De la Serna, J; Fernández-Navarro, JM; Gómez, V; Jarque, I; Jurado, M; López-Jiménez, J; Pascual, A; Romero, M; Serrano, J; Vallejo, C	1
Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J	1
Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E	1
de Witte, T	1
Chung, J; Jang, JH; Jo, DY; Kim, HJ; Lee, JH; Lee, JW; Yoon, SS	1
Cheong, JW; Chung, J; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, HJ; Kim, HY; Lee, JH; Lee, KH; Min, YH; Park, CY; Park, HS; Seong, CM; Shim, H; Sohn, SK; Yoon, HJ; Yoon, SS	1
Gamaletsou, MN; Walsh, TJ	1
Tohyama, K	1
Alimena, G; Angelucci, E; Borin, L; Caocci, G; Cilloni, D; Di Tucci, AA; Fazi, P; Fenu, S; Finelli, C; Latte, G; Molteni, A; Piciocchi, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Storti, S; Tura, S; Vallisa, D; Vignetti, M; Volpe, A; Voso, MT	1
Merkel, DG; Nagler, A	1
Clissa, C; Finelli, C; Stanzani, M	1
Åkerborg, Ö; Björkholm, M; Höglund, M; Lundberg, J	1
Hayakawa, F; Naoe, T; Tomita, A	1
Alimena, G; Angelucci, E; Borin, L; Cilloni, D; Cottone, F; Di Tucci, AA; Efficace, F; Fenu, S; Finelli, C; La Nasa, G; Mandelli, F; Molteni, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Volpe, A; Voso, MT	1
Banerjee, A; Bentley, M; Bird, R; Forsyth, C; Grigg, A; Grigoriadis, G; Kellner, S; Mifsud, NA; Motum, P; Opat, S; Szer, J; Tam, C	1
Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK	1
Alimena, G; Aloe Spiriti, MA; Breccia, M; Buccisano, F; Fenu, S; Maurillo, L; Tafuri, A; Voso, MT	1
Bae, SH; Chung, JS; Hyun, MS; Joo, YD; Kim, H; Kim, HG; Kim, IH; Kim, SH; Kim, YS; Kwon, KY; Lee, GW; Lee, HS; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, KT; Ryoo, HM; Sohn, SK	1
Aloe Spiriti, MA; Breccia, M; Buccisano, F; Criscuolo, M; D'Addosio, A; Fenu, S; Fragasso, A; Latagliata, R; Maurillo, L; Musto, P; Niscola, P; Piccioni, AL; Refrigeri, M; Tatarelli, C; Trapè, G; Venditti, A; Voso, MT	1
Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A	1
Angelucci, E	1
Agaoglu, L; Glaser, S; Kilinç, Y; Kohgo, Y; Lim, LC; Miyamura, K; Urabe, A; Wang, C; Warzocha, K; Wiktor-Jedrzejczak, W	1
Cho, SY; Choi, JH; Choi, JK; Choi, SM; Kim, HJ; Kim, SH; Kim, YJ; Lee, DG; Lee, HJ; Min, WS; Park, SH; Yoo, JH	1
Baer, MR; Davidoff, AJ; Friedmann, E; Gore, SD; Hendrick, F; Paley, C; Sasane, M; Zeidan, AM	1
Angelucci, E; Breccia, M; Gattermann, N; Hofmann, WK; Nolte, F; Santini, V; Vey, N	1
Chan, TS; Gill, H; Hwang, YY; Kwong, YL; Marcella, SW	1
Escudero-Vilaplana, V; Garcia-Gonzalez, X; Osorio-Prendes, S; Romero-Jimenez, RM; Sanjurjo-Saez, M	1
Bruch, HR; Dencausse, Y; Heßling, J; Michl, G; Schlag, R; Schneider-Schranz, C; Schulte, C; Skorupa, A; Tesch, H; Wolf, S	1
Arboscello, E; Biale, L; Del Corso, L; Filiberti, R; Parodi, EL; Russo, R	1
Amdouni, H; Auberger, P; Benhida, R; Bougrin, K; Driowya, M; Dubois, A; Dufies, M; Furstoss, N; Lacas-Gervais, S; Martin, AR; Métier, C; Orange, F; Robert, G; Zerhouni, M	1
Cortoos, A; Goh, AS; Huang, V; Kattamis, A; Kourakli, A; Merino Herranz, R; Origa, R; Perrotta, S; Porter, JB; Ruffo, GB; Taher, AT; Weill, M	1
Hata, T; Ishikawa, T; Kato, J; Kondo, M; Miyazawa, K; Mori, H; Nakao, S; Ohyashiki, K; Omine, M; Ozawa, K; Rojkjaer, L; Taniguchi, J; Tanii, H; Tatsumi, Y; Urabe, A	1
Karthaus, M	1
Brosnahan, G; Gokden, N; Swaminathan, S	1
Jansen, JP; Janssen, JJ; Lugtenburg, E; O'Sullivan, AK; Rijnders, B; Span, LF; Stam, WB	1
Dinter, D; Dorn-Beineke, A; Hastka, J; Hehlmann, R; Leismann, O; Lutz, K; Metzgeroth, G; Schultheis, B	1
AbuTarif, M; Angulo, D; Cornely, OA; Krishna, G; Martinho, M; Xuan, F	1
Arruga, F; Cilloni, D; Messa, E; Messa, F; Roetto, A; Saglio, G	1
Azuma, E; Hosoki, K; Iwamoto, S; Komada, Y; Kumamoto, T	1
Canivet, JL; De Pasqual, A; Deprez, M; Frère, P; Ghaye, B; Hayette, MP; Kaschten, B; Martin, D; Radermecker, M	1
Baltadakis, I; Karakasis, D; Liapis, K; Manaka, K	1
Capalbo, S; Franzese, MG; Palumbo, G; Spinosa, G	1
Baumgartner, C; Nösslinger, T; Pfeilstöcker, M; Sperr, WR; Valent, P; Wimazal, F	1
Kida, M	1
Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Taher, A	1
Stone, RM; Tefferi, A	1
Cernik, C; Haller, N; Mostow, EN	1
Arrizabalaga, B; Del Cañizo, C; Remacha, AF; Sanz, G; Villegas, A	1
Hansel-Esteller, S; Selvy, N; Villiet, M	1
Cappellini, MD; Taher, A	1
Alvarado, G; Blamble, D; Cortes, J; Faderl, S; Hernandez, M; Kantarjian, H; Koller, C; Mattiuzzi, GN; Pierce, S; Verstovsek, S; Xiao, L	1
AbuTarif, MA; Krishna, G; Statkevich, P	1
HATANO, K; MATSUYAMA, T; MORI, M; MUROI, K; NAGAI, T; OKABE, H; OMORI, T; OZAWA, K; QZAKI, K; SUZUKI, T; TOSHIMA, M; UEDA, M; UEHARA, E	1
Cornely, OA; Rüping, MJ; Vehreschild, JJ	1
Schmid, M	1
Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K	1
Alati, C; Marino, A; Nobile, F; Oliva, EN; Praticò, G; Ronco, F	1
Fausel, CA	1
Greiner, RA; Imhof, A; Meier, Y; O'Sullivan, AK; Papadopoulos, G	1
Fibach, E; Ghoti, H; Grisariu, S; Merkel, D; Perez-Avraham, G; Rachmilewitz, EA	1
Domokos, G; Fenaux, P; Finelli, C; Ganser, A; Gattermann, N; Guerci-Bresler, A; Habr, D; Porta, MD; Rose, C; Roubert, B; Schmid, M; Taylor, K; Vassilieff, D	1
Alberti, D; Arruga, F; Bracco, E; Carturan, S; Cilloni, D; Defilippi, I; Greco, E; Maffè, C; Messa, E; Messa, F; Pautasso, M; Pellegrino, RM; Roetto, A; Rosso, V; Rotolo, A; Saglio, G; Zanone, C	1
Lazzaro, C	1
Cabantchik, ZI; Glynos, T; Greenberg, PL; Koller, CA; Paley, C; Schiffer, C; Warsi, G	1
Alimena, G; Breccia, M; Cannella, L; Loglisci, G; Salaroli, A; Santopietro, M	1
Leitch, HA	1
Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K	1
Tefferi, A	2
Dranitsaris, G; Khoury, H	1
Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G	1
Langston, AA; Mehta, AK	1
Bianchino, G; Bochicchio, GB; D'Auria, F; Grieco, V; Guariglia, R; Lerose, R; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O	1
Bryant, AM; Craig, M; Cumpston, A; Slain, D	1
Fibach, E; Ganz, T; Ghoti, H; Gordana, O; Rachmilewitz, EA; Westerman, M	1
Patel, P; Rondelli, D; Sweiss, K	1
Almeida, A; Angelucci, E; Beris, P; Guerci-Bresler, A; Hofmann, WK; Macwhannell, A; Muus, P; Nolte, F; Porter, J; Schumann, C; Selleslag, D; Sliwa, T; Xicoy, B	1
Blumenstengel, K; Gattermann, N; Germing, U; Goebeler, M; Groschek, M; Jarisch, A; Junkes, A; Leismann, O; Losem, C; Procaccianti, M; Schlag, R	1
Ananda-Rajah, MR; Bajel, A; Cheng, A; Downey, MT; Grigg, A; Slavin, MA; Spelman, T; Thursky, KT; Vincent, J	1
Berard, F; Martin, O; Nicolas, JF; Rozieres, A; Said, BB	1
Kontoyiannis, DP	1
Cornely, OA; Farowski, F; Fuhr, U; Hallek, M; Kohl, V; Kreuzer, KA; Müller, C; Vehreschild, JJ; Vehreschild, MJ	1
Miyazaki, Y	1
Kato, J; Matsuki, E; Matsumoto, K; Nakaya, A; Okamoto, S; Yamane, A	1
Della Porta, M; Fenaux, P; Finelli, C; Gattermann, N; Guerci-Bresler, A; Habr, D; Marcellari, A; Rose, C; Roubert, B; Schmid, M; Stadler, M; Taylor, K; Vassilieff, D	1
Bhatia, R; Forman, S; Li, L; Lin, A; Meng, Z; Pullarkat, V; Sehgal, A	1
Araki, H; Hara, T; Moriwaki, H; Oyama, M; Tsurumi, H; Yoshikawa, T	1
Baer, MR; Besa, E; Esposito, J; Feigert, J; List, AF; Martinez-Lopez, N; Paley, C; Raza, A; Steensma, DP	1
Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A	1
Fibach, E; Rachmilewitz, EA	1
Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S	1
Hayashi, T; Iyama, S; Kaneko, Y; Kato, J; Kawano, Y; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Ono, K; Sato, T; Sato, Y; Takada, K; Takimoto, R	1
Arnan, M; Bermúdez, A; Caballero, T; Duarte, RF; Montes, C; Patiño, B; Sánchez-Ortega, I; Vázquez, L; Yáñez, L	1
Ameye, L; Aoun, M; Bourguignon, AM; Bron, D; Cotton, F; Csergö, M; Hites, M; Jacobs, F; Rasson, C; Vaes, M	1
Baier, M; Gattermann, N; Giagounidis, A; Haase, D; Höchsmann, B; Hofmann, WK; Junkes, A; Leismann, O; Lübbert, M; Lück, A; Nolte, F; Platzbecker, U; Schrezenmeier, H; Schumann, C; Taupitz, M	1
Maekawa, T; Yoshioka, S	1
Ruivard, M	1
Braulke, F; Haase, D; Hartmann, J; Konietschke, F; Maas, JH; Sinzig, U; Wulf, G	1
Barberán, J; Carreras, E; Jarque, I; Mensa, J; Serrano, D; Vázquez, L	1
Basso, C; Biffanti, R; Milanesi, O; Stellin, G; Thiene, G; Vida, V	1
Alaggio, R; Calore, E; Cesaro, S; Cusinato, R; Messina, C; Pillon, M; Toffolutti, T; Zanesco, L	1
Greenberg, PL	1
Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ	1
Steensma, DP; Tefferi, A	1
Barton, JC	1
van Dissel, JT; van Nieuwkoop, C	1
Alberti, D; Alimena, G; Cappellini, MD; Cario, H; Cazzola, M; Cunningham, MJ; Debusscher, L; Della Porta, M; Ford, JM; Forni, GL; Galanello, R; Gathmann, I; Gattermann, N; Giardina, P; Greenberg, P; Jeng, M; Kwiatkowski, J; Maertens, J; Neufeld, EJ; Olivieri, N; Piga, A; Porter, J; Quarta, G; Rabault, B; Rose, C; Saglio, G; Soulières, D; Stadler, M; Tchernia, G; Vichinsky, E	1
Goldberg, SL	1
Almyroudis, NG; Gonzalez, AV; Segal, BH; Ullmann, AJ	1
Ohyashiki, K	1
Hojo, H; Lin, KY; Torii, Y; Toyama, K; Tsuda, A; Yoshikawa, O	1

Reviews

27 review(s) available for triazoles and Myelodysplastic Syndromes

Article	Year
[Transfusions in myelodysplastic syndromes]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2017, Volume: 24, Issue:3 Topics: Benzoates; Blood Grouping and Crossmatching; Combined Modality Therapy; Deferasirox; Erythrocyte Transfusion; Hematinics; Hemoglobins; Hepcidins; Humans; Intestinal Absorption; Iron Chelating Agents; Iron Overload; Iron, Dietary; Myelodysplastic Syndromes; Patient Satisfaction; Quality of Life; Rh Isoimmunization; Triazoles	2017
Iron overload in myelodysplastic syndromes (MDS). International journal of hematology, 2018, Volume: 107, Issue:1 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestinal Mucosa; Iron; Iron Chelating Agents; Iron Overload; Liver; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles	2018
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Annals of hematology, 2018, Volume: 97, Issue:2 Topics: Antifungal Agents; Clinical Trials as Topic; Drug Monitoring; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Induction Chemotherapy; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Medical Oncology; Myelodysplastic Syndromes; Primary Prevention; Societies, Medical; Triazoles; Voriconazole	2018
Efficacy and safety of deferasirox in myelodysplastic syndromes. Annals of hematology, 2013, Volume: 92, Issue:7 Topics: Benzoates; Chelation Therapy; Clinical Trials, Phase II as Topic; Deferasirox; Drug Eruptions; Drug Therapy, Combination; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Multicenter Studies as Topic; Myelodysplastic Syndromes; NF-kappa B; Oxidative Stress; Prospective Studies; Retrospective Studies; Survival Analysis; Transfusion Reaction; Triazoles	2013
Treatment of fungal disease in the setting of neutropenia. Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013 Topics: Anemia, Aplastic; Antifungal Agents; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Fusariosis; Fusarium; Hematologic Neoplasms; Humans; Myelodysplastic Syndromes; Neutropenia; Pyrimidines; Scedosporium; Triazoles; Voriconazole	2013
[Myelodysplastic syndromes: treatment strategy up-to-date]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1 Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles	2014
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes. Expert review of anticancer therapy, 2014, Volume: 14, Issue:7 Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles	2014
Deferasirox for managing iron overload in people with myelodysplastic syndrome. The Cochrane database of systematic reviews, 2014, Oct-28, Issue:10 Topics: Benzoates; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles	2014
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. Annals of hematology, 2015, Volume: 94, Issue:5 Topics: Benzoates; Blood Platelets; Chelation Therapy; Deferasirox; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Leukocytes; Myelodysplastic Syndromes; Triazoles	2015
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations. Leukemia research, 2015, Volume: 39, Issue:10 Topics: Benzoates; Chelation Therapy; Deferasirox; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles	2015
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. The oncologist, 2009, Volume: 14, Issue:5 Topics: Administration, Oral; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles	2009
Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:11 Topics: Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Platelet Transfusion; Treatment Outcome; Triazoles	2009
Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? Leukemia & lymphoma, 2010, Volume: 51, Issue:1 Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Clinical Trials as Topic; Drug Resistance, Fungal; Echinocandins; Fever; Humans; Leukemia, Myeloid, Acute; Lipopeptides; Medical Oncology; Mycoses; Myelodysplastic Syndromes; Triazoles	2010
Iron chelation therapy in MDS: what have we learnt recently? Blood reviews, 2009, Volume: 23 Suppl 1 Topics: Benzoates; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles	2009
Deferasirox for managing iron overload in people with myelodysplastic syndrome. The Cochrane database of systematic reviews, 2010, Nov-10, Issue:11 Topics: Benzoates; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles	2010
Use of posaconazole in the treatment of invasive fungal infections. Expert review of hematology, 2009, Volume: 2, Issue:6 Topics: Animals; Antifungal Agents; Clinical Trials as Topic; Drug Resistance, Fungal; Fungi; Graft vs Host Disease; Humans; Immunocompromised Host; Leukemia, Myeloid; Mice; Mycoses; Myelodysplastic Syndromes; Rabbits; Stem Cell Transplantation; Triazoles; United States	2009
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leukemia research, 2011, Volume: 35, Issue:5 Topics: Administration, Oral; Aged; Benzoates; Chelation Therapy; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles; Up-Regulation	2011
Invasive mycoses: strategies for effective management. The American journal of medicine, 2012, Volume: 125, Issue:1 Suppl Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Antifungal Agents; Antineoplastic Agents; Aspartate Aminotransferases; Aspergillosis; Bilirubin; Biomarkers; Drug Monitoring; Echinocandins; Female; Flucytosine; Humans; Immunocompromised Host; Leukemia; Liver; Liver Function Tests; Male; Middle Aged; Mucormycosis; Mycoses; Myelodysplastic Syndromes; Opportunistic Infections; Pneumonia; Risk Factors; Triazoles	2012
[MDS]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1 Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles	2012
Management of transfusion-related iron overload in patients with myelodysplastic syndromes. Clinical journal of oncology nursing, 2012, Volume: 16 Suppl Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles	2012
[Iron chelating therapy in adults: How and when ?]. La Revue de medecine interne, 2013, Volume: 34, Issue:1 Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles	2013
Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Journal of the National Comprehensive Cancer Network : JNCCN, 2006, Volume: 4, Issue:1 Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles	2006
Risk-based management of myelodysplastic syndrome. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:1 Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles	2007
Chelation therapy for iron overload. Current gastroenterology reports, 2007, Volume: 9, Issue:1 Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles	2007
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leukemia research, 2007, Volume: 31 Suppl 3 Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Survival Rate; Transfusion Reaction; Treatment Outcome; Triazoles	2007
Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6, Issue:2 Topics: Antifungal Agents; Fluconazole; Humans; Immunocompromised Host; Itraconazole; Mycoses; Myelodysplastic Syndromes; Neoplasms; Neutropenia; Risk Assessment; Triazoles	2008
[Development trend in new therapeutic approaches for anemia]. Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:3 Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles	2008

Trials

28 trial(s) available for triazoles and Myelodysplastic Syndromes

Article	Year
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia, 2022, Volume: 36, Issue:9 Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles	2022
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial. Leukemia, 2023, Volume: 37, Issue:11 Topics: Benzocycloheptenes; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles	2023
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 05-18, Volume: 72, Issue:10 Topics: Adult; Aged; Antifungal Agents; Humans; Leukemia, Myeloid, Acute; Mycoses; Myelodysplastic Syndromes; Nitriles; Prospective Studies; Pyridines; Triazoles	2021
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone marrow transplantation, 2020, Volume: 55, Issue:11 Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles	2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. The Lancet. Haematology, 2020, Volume: 7, Issue:8 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles	2020
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. The Journal of antimicrobial chemotherapy, 2017, Dec-01, Volume: 72, Issue:12 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunocompromised Host; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles; Young Adult	2017
Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study. The Journal of infection, 2018, Volume: 77, Issue:3 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antifungal Agents; Chemoprevention; Female; Humans; Incidence; Leukemia; Male; Micafungin; Middle Aged; Mycoses; Myelodysplastic Syndromes; Neutropenia; Survival Analysis; Treatment Failure; Triazoles	2018
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Transfusion, 2014, Volume: 54, Issue:6 Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles	2014
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). European journal of haematology, 2014, Volume: 92, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2014
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload. Transfusion, 2015, Volume: 55, Issue:7 Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles	2015
Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias. Acta haematologica, 2015, Volume: 134, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Deferasirox; Humans; Iron Overload; Liver; Middle Aged; Myelodysplastic Syndromes; Triazoles	2015
CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload. Oncology research and treatment, 2016, Volume: 39, Issue:7-8 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles	2016
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. American journal of hematology, 2017, Volume: 92, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chemistry, Pharmaceutical; Child; Deferasirox; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Quality of Life; Tablets, Enteric-Coated; Thalassemia; Triazoles; Young Adult	2017
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. International journal of hematology, 2008, Volume: 88, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Asian People; Benzoates; Blood Transfusion; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles	2008
Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study. Annals of hematology, 2009, Volume: 88, Issue:4 Topics: Aged; Aged, 80 and over; Benzoates; Bone Marrow; Deferasirox; Ferritins; Humans; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles	2009
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy, 2008, Volume: 28, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Antineoplastic Agents; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Single-Blind Method; Triazoles; Young Adult	2008
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Bilirubin; Drug Monitoring; Female; Humans; Infusions, Intravenous; Itraconazole; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Prospective Studies; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole; Young Adult	2011
Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Current medical research and opinion, 2010, Volume: 26, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Neutropenia; Population; Single-Blind Method; Triazoles; Young Adult	2010
Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica, 2010, Volume: 95, Issue:8 Topics: Administration, Oral; Aged; Benzoates; Biomarkers; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Oxidative Stress; Time Factors; Treatment Outcome; Triazoles	2010
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leukemia research, 2010, Volume: 34, Issue:9 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles; Young Adult	2010
[Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome]. Le infezioni in medicina, 2010, Volume: 18, Issue:2 Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycholic Acid; Drug Combinations; Drug Costs; Equipment and Supplies; Fluconazole; Follow-Up Studies; Hospital Costs; Humans; Immunocompromised Host; Infusions, Intravenous; Italy; Itraconazole; Leukemia, Myeloid, Acute; Mycoses; Myelodysplastic Syndromes; Neutropenia; Oncology Nursing; Treatment Outcome; Triazoles	2010
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leukemia research, 2010, Volume: 34, Issue:12 Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles	2010
Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. British journal of haematology, 2011, Volume: 153, Issue:1 Topics: Aged; Antimicrobial Cationic Peptides; Benzoates; Blood Transfusion; Deferasirox; Erythropoiesis; Female; Hepcidins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Oxidative Stress; Transferrin; Triazoles	2011
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica, 2012, Volume: 97, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Deferasirox; Female; Follow-Up Studies; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Prospective Studies; Survival Rate; Transfusion Reaction; Triazoles; Young Adult	2012
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-10, Volume: 30, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron; Iron Chelating Agents; Male; Membrane Proteins; Middle Aged; Mutation; Myelodysplastic Syndromes; Prospective Studies; Time Factors; Treatment Outcome; Triazoles	2012
Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:12 Topics: Adolescent; Adult; Aged; Antifungal Agents; Biological Availability; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Food-Drug Interactions; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prospective Studies; Spectrophotometry, Ultraviolet; Tacrolimus; Triazoles; Young Adult	2012
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Creatinine; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Treatment Outcome; Triazoles	2013
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. The New England journal of medicine, 2007, Jan-25, Volume: 356, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Female; Fluconazole; Humans; Itraconazole; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Neutropenia; Opportunistic Infections; Single-Blind Method; Treatment Outcome; Triazoles	2007

Other Studies

80 other study(ies) available for triazoles and Myelodysplastic Syndromes

Article	Year
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. Investigational new drugs, 2022, Volume: 40, Issue:4 Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53	2022
Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia. Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:10 Topics: Anemia, Aplastic; Benzoates; Creatinine; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles	2022
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. British journal of haematology, 2017, Volume: 177, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome; Triazoles	2017
Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. Advances in therapy, 2017, Volume: 34, Issue:9 Topics: Adult; Aged; Antifungal Agents; Cost-Benefit Analysis; Female; Fluconazole; Humans; Invasive Fungal Infections; Itraconazole; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Economic; Myelodysplastic Syndromes; Solutions; Spain; Tablets; Triazoles	2017
Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison. Mycoses, 2018, Volume: 61, Issue:3 Topics: Adult; Aged; Antifungal Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Invasive Fungal Infections; Invasive Pulmonary Aspergillosis; Itraconazole; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pre-Exposure Prophylaxis; Retrospective Studies; Treatment Failure; Triazoles	2018
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit? Leukemia research, 2018, Volume: 64 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyridones; Retrospective Studies; Triazoles	2018
Successful Treatment of Lung Aspergillus terreus Infection After a Second Hematopoietic Stem Cell Transplant in a Patient With Myelodysplastic Syndrome. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2019, Volume: 17, Issue:3 Topics: Antifungal Agents; Hematopoietic Stem Cell Transplantation; Humans; Male; Micafungin; Myelodysplastic Syndromes; Postoperative Complications; Pulmonary Aspergillosis; Remission Induction; Triazoles; Young Adult	2019
Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. Anais brasileiros de dermatologia, 2017, Volume: 92, Issue:5 Suppl 1 Topics: Aged; Benzoates; Biopsy; Deferasirox; Drug Eruptions; Female; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Triazoles; Urticaria; Vasculitis	2017
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018, Volume: 24 Suppl 1 Topics: Antibodies, Fungal; Antifungal Agents; Aspergillosis; Aspergillus; Biopsy; Bronchoalveolar Lavage; Disease Management; Early Diagnosis; Flucytosine; Galactose; Humans; Immunocompromised Host; Immunologic Tests; Invasive Pulmonary Aspergillosis; Itraconazole; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Mannans; Microbial Sensitivity Tests; Myelodysplastic Syndromes; Nitriles; Pyridines; Tomography, X-Ray Computed; Triazoles; Voriconazole	2018
Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:2 Topics: Adult; Aged; Antifungal Agents; Female; Humans; Induction Chemotherapy; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Triazoles; Voriconazole	2019
Subtherapeutic posaconazole troughs despite high-dose posaconazole tablets in a patient with terminal ileum resection. The Journal of infection, 2019, Volume: 78, Issue:5 Topics: Humans; Ileum; Leukemia; Micafungin; Myelodysplastic Syndromes; Tablets; Triazoles	2019
The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. American journal of hematology, 2013, Volume: 88, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Neutropenia; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rhizopus; Triazoles; Voriconazole	2013
A case of late onset erythropoietic protoporphyria associated with myelodysplastic syndrome treated by the combination of beta carotene and azacitidine. Annals of hematology, 2013, Volume: 92, Issue:10 Topics: Aged; Azacitidine; Benzoates; beta Carotene; Deferasirox; Humans; Male; Myelodysplastic Syndromes; Protoporphyria, Erythropoietic; Triazoles	2013
Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2013, Volume: 26, Issue:1 Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Candidiasis, Invasive; Child; Child, Preschool; Combined Modality Therapy; Cross Infection; Drug Evaluation; Female; Fungemia; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infant; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Postoperative Complications; Retrospective Studies; Risk; Transplantation, Homologous; Treatment Outcome; Triazoles; Young Adult	2013
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leukemia research, 2013, Volume: 37, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles	2013
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment? Leukemia & lymphoma, 2014, Volume: 55, Issue:6 Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles	2014
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival? Leukemia research, 2013, Volume: 37, Issue:12 Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles	2013
Korean guideline for iron chelation therapy in transfusion-induced iron overload. Journal of Korean medical science, 2013, Volume: 28, Issue:11 Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Republic of Korea; Transfusion Reaction; Triazoles	2013
[The role of iron metabolism in myelodysplastic syndromes]. Recenti progressi in medicina, 2014, Volume: 105, Issue:3 Topics: Anemia; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Triazoles	2014
Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden. Clinical drug investigation, 2014, Volume: 34, Issue:7 Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Neutropenia; Quality of Life; Quality-Adjusted Life Years; Sweden; Triazoles	2014
Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:4 Topics: Acute Disease; Administration, Oral; Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Triazoles	2014
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. BMJ supportive & palliative care, 2016, Volume: 6, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2016
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. British journal of haematology, 2015, Volume: 168, Issue:4 Topics: Anemia, Aplastic; Animals; Benzoates; Bone Marrow Cells; Cell Line; Cells, Cultured; Deferasirox; Deferoxamine; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Macrophages; Male; Mice; Myelodysplastic Syndromes; NF-kappa B; RNA, Long Noncoding; Transcription, Genetic; Triazoles; Tumor Necrosis Factor-alpha	2015
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. European journal of haematology, 2015, Volume: 95, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles	2015
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. European journal of haematology, 2016, Volume: 96, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fluconazole; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Pre-Exposure Prophylaxis; Remission Induction; Retrospective Studies; Survival Analysis; Triazoles	2016
Another Step Forward in Iron Chelation Therapy. Acta haematologica, 2015, Volume: 134, Issue:4 Topics: Anemia, Aplastic; Benzoates; Humans; Iron Overload; Liver; Myelodysplastic Syndromes; Triazoles	2015
Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. Mycoses, 2015, Volume: 58, Issue:9 Topics: Adult; Antifungal Agents; Female; Fluconazole; Humans; Incidence; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Remission Induction; Republic of Korea; Retrospective Studies; Time Factors; Triazoles	2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. Journal of comparative effectiveness research, 2015, Volume: 4, Issue:4 Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Medicare; Myelodysplastic Syndromes; Risk Reduction Behavior; Triazoles; United States	2015
Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. Journal of medical economics, 2016, Volume: 19, Issue:1 Topics: Antifungal Agents; Cost-Benefit Analysis; Decision Support Techniques; Fluconazole; Hong Kong; Hospitals, Teaching; Humans; Itraconazole; Leukemia, Myeloid, Acute; Models, Econometric; Mycoses; Myelodysplastic Syndromes; Socioeconomic Factors; Triazoles	2016
Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome. Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:1 Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Follow-Up Studies; Hospitals, University; Humans; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles	2016
Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients. International journal of clinical oncology, 2017, Volume: 22, Issue:2 Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles	2017
In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies. Journal of medicinal chemistry, 2017, 02-23, Volume: 60, Issue:4 Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycosides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mice, Nude; Myelodysplastic Syndromes; Triazoles; Tumor Cells, Cultured	2017
Treatment of aspergillosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Aug-01, Volume: 47, Issue:3 Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neutropenia; Triazoles	2008
Acute interstitial nephritis due to deferasirox: a case report. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:10 Topics: Acute Disease; Benzoates; Deferasirox; Drug Hypersensitivity; Eosinophils; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Nephritis, Interstitial; Triazoles	2008
Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. European journal of haematology, 2008, Volume: 81, Issue:6 Topics: Adult; Aged; Antifungal Agents; Costs and Cost Analysis; Female; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Econometric; Mycoses; Myelodysplastic Syndromes; Netherlands; Neutropenia; Randomized Controlled Trials as Topic; Triazoles	2008
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta haematologica, 2008, Volume: 120, Issue:2 Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles	2008
Early detection of breakthrough trichosporonosis by serum PCR in a cord blood transplant recipient being prophylactically treated with voriconazole. Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:12 Topics: Adolescent; Antifungal Agents; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; DNA, Fungal; Fungemia; Humans; Male; Mycoses; Myelodysplastic Syndromes; Polymerase Chain Reaction; Prognosis; Pyrimidines; Triazoles; Trichosporon; Voriconazole	2008
[Invasive pulmonary mucormycosis with invasion of the thoracic spine in a patient with myelodysplastic syndrome]. Revue medicale de Liege, 2008, Volume: 63, Issue:12 Topics: Aged; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Fatal Outcome; Humans; Immunocompromised Host; Laminectomy; Lung Diseases, Fungal; Male; Mucormycosis; Myelodysplastic Syndromes; Spinal Diseases; Thoracic Vertebrae; Triazoles	2008
Cerebral aspergillosis. European journal of haematology, 2009, Volume: 82, Issue:4 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Brain; Brain Abscess; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mood Disorders; Myelodysplastic Syndromes; Personality; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Triazoles; Voriconazole	2009
Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta haematologica, 2009, Volume: 121, Issue:1 Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles	2009
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. European journal of clinical investigation, 2009, Volume: 39, Issue:5 Topics: Administration, Oral; Aged; Benzoates; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Triazoles	2009
[Two cases of mycoses associated with hematologic disease]. The Japanese journal of antibiotics, 2008, Volume: 61, Issue:5 Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Cunninghamella; Fatal Outcome; Humans; Liposomes; Male; Mucormycosis; Myelodysplastic Syndromes; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole	2008
Iron chelation therapy in myelodysplastic syndrome - Cui bono? Leukemia, 2009, Volume: 23, Issue:8 Topics: Aged; Benzoates; Biomarkers; Chelation Therapy; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Life Expectancy; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles	2009
Adult-onset erythropoietic porphyria in the setting of MDS. Archives of dermatology, 2009, Volume: 145, Issue:8 Topics: Aged, 80 and over; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Male; Myelodysplastic Syndromes; Porphyria, Erythropoietic; Triazoles	2009
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Annals of hematology, 2010, Volume: 89, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Triazoles	2010
[Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study]. Pathologie-biologie, 2010, Volume: 58, Issue:2 Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Therapy, Combination; Esomeprazole; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Neutropenia; Oncology Service, Hospital; Postoperative Complications; Premedication; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Triazoles	2010
Deferasirox (Exjade) for the treatment of iron overload. Acta haematologica, 2009, Volume: 122, Issue:2-3 Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles	2009
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome. International journal of hematology, 2010, Volume: 91, Issue:2 Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles	2010
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion, 2010, Volume: 50, Issue:7 Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; Deferasirox; Female; Hematopoiesis; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles	2010
Iron chelation therapy in myelodysplastic syndromes. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, Volume: 67, Issue:7 Suppl 2 Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Quality-Adjusted Life Years; Siderophores; Treatment Outcome; Triazoles	2010
Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology, 2010, Volume: 78, Issue:3-4 Topics: Cost-Benefit Analysis; Decision Support Techniques; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Markov Chains; Models, Theoretical; Mycoses; Myelodysplastic Syndromes; Neutropenia; Risk; Switzerland; Treatment Outcome; Triazoles	2010
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica, 2010, Volume: 95, Issue:8 Topics: Aged; Aged, 80 and over; Apoptosis; Benzoates; Blotting, Western; Deferasirox; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Iron; Iron Chelating Agents; K562 Cells; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; NF-kappa B; Protein Binding; Reactive Oxygen Species; Triazoles	2010
Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta haematologica, 2010, Volume: 124, Issue:1 Topics: Benzoates; Blood Transfusion; Deferasirox; Erythroid Cells; Ferritins; Hemoglobins; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles	2010
Delineating parameters of iron overload in MDS patients treated with deferasirox. Leukemia research, 2010, Volume: 34, Issue:12 Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles	2010
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. Journal of medical economics, 2010, Volume: 13, Issue:3 Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Insurance Claim Review; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Siderophores; State Medicine; Survival Analysis; Triazoles; United Kingdom	2010
Myelodysplastic syndromes--many new drugs, little therapeutic progress. Mayo Clinic proceedings, 2010, Volume: 85, Issue:11 Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles	2010
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:11 Topics: Antifungal Agents; Antineoplastic Agents; Canada; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Models, Economic; Mycoses; Myelodysplastic Syndromes; Neoplasms; Randomized Controlled Trials as Topic; Triazoles	2011
A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. International journal of antimicrobial agents, 2011, Volume: 37, Issue:3 Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Drug Monitoring; Female; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Triazoles	2011
Deferasirox increases BU blood concentrations. Bone marrow transplantation, 2012, Volume: 47, Issue:2 Topics: Benzoates; Busulfan; Deferasirox; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles	2012
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leukemia research, 2011, Volume: 35, Issue:9 Topics: Benzoates; Chelation Therapy; Deferasirox; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Practice Guidelines as Topic; Triazoles	2011
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. European journal of haematology, 2012, Volume: 88, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles	2012
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica, 2012, Volume: 97, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antifungal Agents; Female; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Male; Medication Adherence; Middle Aged; Mycoses; Myelodysplastic Syndromes; Pyrimidines; Retrospective Studies; Treatment Outcome; Triazoles; Voriconazole; Young Adult	2012
Severe hypocalcemia and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome under deferasirox therapy for myelodysplasic syndrome. American journal of hematology, 2012, Volume: 87, Issue:2 Topics: Aged; Benzoates; Deferasirox; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Female; Humans; Hypocalcemia; Iron Chelating Agents; Myelodysplastic Syndromes; Syndrome; Triazoles	2012
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. European journal of clinical pharmacology, 2012, Volume: 68, Issue:6 Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Cohort Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Models, Biological; Mycoses; Myelodysplastic Syndromes; Suspensions; Triazoles; Young Adult	2012
[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1 Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles	2012
Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors. Leukemia research, 2012, Volume: 36, Issue:8 Topics: Aged; Aged, 80 and over; Benzoates; Cell Proliferation; Cell Survival; Cells, Cultured; Deferasirox; Down-Regulation; Female; Fetal Blood; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Reactive Oxygen Species; Triazoles; Up-Regulation	2012
First report of drug-induced esophagitis by deferasirox. International journal of hematology, 2012, Volume: 95, Issue:6 Topics: Benzoates; Deferasirox; Esophagitis; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles	2012
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. Annals of hematology, 2012, Volume: 91, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles	2012
Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS. Leukemia research, 2012, Volume: 36, Issue:8 Topics: Benzoates; Cell Proliferation; Deferasirox; Female; Hematopoietic Stem Cells; Humans; Male; Myelodysplastic Syndromes; Reactive Oxygen Species; Triazoles	2012
Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free radical biology & medicine, 2012, Aug-15, Volume: 53, Issue:4 Topics: 8-Hydroxy-2'-Deoxyguanosine; Antigens, CD; Benzoates; Case-Control Studies; Deferasirox; Deoxyguanosine; DNA Damage; Erythrocyte Transfusion; Ferritins; Genome, Human; Humans; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Prospective Studies; Reactive Oxygen Species; Statistics, Nonparametric; Triazoles	2012
Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:12 Topics: Adolescent; Adult; Aged; Antifungal Agents; Blood Transfusion; Bone Marrow Transplantation; Cyclosporine; Drug Interactions; Drug Monitoring; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Lymphoproliferative Disorders; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Triazoles; Young Adult	2012
[Transfusion reaction and HLA antibodies]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2 Topics: Acute Lung Injury; Antibody Formation; Benzoates; Blood Transfusion; Deferasirox; Hematologic Neoplasms; Hemochromatosis; HLA Antigens; Humans; Iron Chelating Agents; Isoantibodies; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles	2012
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leukemia research, 2013, Volume: 37, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Cell Count; Cell Proliferation; Cohort Studies; Deferasirox; Erythroid Precursor Cells; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles	2013
Antifungal prophylaxis in the haematological patient: a practical approach. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2012, Volume: 25, Issue:4 Topics: Algorithms; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Biological Availability; Decision Trees; Drug Interactions; Echinocandins; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Diseases; Mycoses; Myelodysplastic Syndromes; Postoperative Complications; Practice Guidelines as Topic; Premedication; Triazoles	2012
Images in cardiovascular medicine. Left ventricular mass after treatment with chemotherapic drugs. Circulation, 2004, Jun-01, Volume: 109, Issue:21 Topics: Acute Disease; Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; Aspergillus; Combined Modality Therapy; Echocardiography; Heart Septum; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Pyrimidines; Triazoles; Ventricular Outflow Obstruction; Voriconazole	2004
Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. European journal of haematology, 2004, Volume: 73, Issue:1 Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus flavus; Aspergillus fumigatus; Caspofungin; Child; Drug Synergism; Drug Therapy, Combination; Echinocandins; Female; Geotrichosis; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lipopeptides; Liposomes; Male; Mycoses; Myelodysplastic Syndromes; Peptides; Peptides, Cyclic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Treatment Outcome; Triazoles; Voriconazole	2004
Iron chelation therapy for myelodysplastic syndrome: if and when. Mayo Clinic proceedings, 2006, Volume: 81, Issue:2 Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Survival Rate; Triazoles	2006
Posaconazole prophylaxis in hematologic cancer. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Antifungal Agents; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Mycoses; Myelodysplastic Syndromes; Opportunistic Infections; Research Design; Triazoles	2007
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. European journal of haematology, 2008, Volume: 80, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Diamond-Blackfan; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles	2008
[A clinical evaluation of injectable fluconazole in the treatment of deep mycosis associated with hematological malignancy]. The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Candida; Candidiasis; Drug Evaluation; Drug Tolerance; Female; Fluconazole; Humans; Injections, Intravenous; Leukemia; Lymphoma; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Triazoles	1989